Breast Fat Grafting vs Stem Cell Breast Augmentation
아래 사실은 모두 두 엔티티 페이지와 그 출처에서 가져온 것입니다. 양쪽이 함께 기록한 항목을 먼저 대조하고, 나머지는 나란히 보여 줍니다.
의료
Breast Fat GraftingBreast fat grafting (fat transfer breast augmentation) uses the patient's own liposuctioned fat to modestly enlarge or reshape the breast without an implant.갱신 2026년 9월 20일개념
Stem Cell Breast AugmentationA consumer and marketing term for breast fat grafting enriched with stromal vascular fraction or adipose-derived cells. It is not a separate regulated procedure category.갱신 2026년 9월 21일둘의 관계Breast Fat Grafting — 관련 → Stem Cell Breast Augmentation
공통 항목
양쪽 모두 기록된 항목 0개두 항목이 공통으로 기록한 항목이 아직 없습니다. 각각의 검증된 사실은 아래에 있습니다.
각각의 사실
둘 중 한쪽에만 기록된 검증된 사실입니다.
Breast Fat Grafting
DefinitionFat is taken by liposuction from other parts of the body and injected to enlarge the breasts
Typical donor sitesUsually the abdomen or flanks, though fat can be taken from almost anywhere (surgeon quoted by ASPS)
Typical size increaseSurgeon quoted by ASPS: ideal candidate wants half a cup to one cup; a larger increase may take two to three procedures
Listed risksCysts, infection, microcalcification, death of fat cells (necrosis), and some transferred fat leaving the breast area
Pre-expansion optionSurgeons may recommend an external tissue expansion system in the weeks before surgery
Pooled volume retention54% (95% CI 48.5–59.5%) across 25 studies, follow-up 3–36 months
Retention by fat preparation methodCentrifugation 51.5% vs sedimentation 38.7% pooled retention
Oncologic safety evidenceMeta-analysis of 15 studies (8,541 participants): no difference in overall survival, disease-free survival or local recurrence between patients who had fat grafting after breast cancer surgery and controls
1987 professional positionASPRS (predecessor of ASPS) condemned autologous fat injection for breast augmentation over concerns about cancer detection
2009 ASPS Fat Graft Task ForceConcluded that the literature then available showed no association between fat grafting and higher rates of malignancy
US regulatory statusFollowing FDA guidance issued in November 2017, autologous fat grafts do not require premarket approval; stromal vascular fraction products receive closer review
Relevant FDA guidanceSame Surgical Procedure Exception under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception
Suitable forPeople wanting a relatively small increase in breast size who have enough donor fat (ASPS)
SessionsMore than one session may be needed because part of the graft is resorbed
Imaging noteFat necrosis, cysts and calcifications can appear on mammograms and must be interpreted by a radiologist
Stem Cell Breast Augmentation
아직 검증된 값이 없습니다